This collection
is approved as it pertains to the previous rule approved in 1993.
OMB files comment on this collection as it pertains to the new
proposed rule, and FDA will resubmit this collection with any
changes along with the final rule. In drafting the final rule and
paperwork submission, FDA should consider uses of appropriate
technology (e.g. electronic submission of information) that could
reduce burden. This collection was used without OMB approval by FDA
in conjunction with a previous rule. FDA will take steps to ensure
that this does not happen with future collections.
Inventory as of this Action
Requested
Previously Approved
05/31/2003
05/31/2003
10,175,490
0
0
2,790,693
0
0
0
0
0
Manufacturers receiving FDA orders to
track a device, whose failure would likely have serious adverse
health consequences, and which is implanted in humans for more than
1 year, or is life-sustaining or life-supporting and used outside a
device user facility, are required to collect/maintain current
tracking information about the identity and location of the device
during distribution, and about the identity and location of
patients receiving the device, including certian physician
information. Distributors must report this date to manufacturers.
Such information must be made available by manufacturers within 3
or..
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.